Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11303483 | 1.00 | DPP7 (0.39) | DPP7ABCB1 | |
| SCHEMBL27150404 | 1.00 | DPP7 (0.39) | DPP7ABCB1 | |
| SCHEMBL27137288 | 1.00 | DPP7 (0.39) | DPP7ABCB1 | |
| SCHEMBL11299622 | 1.00 | DPP7 (0.39) | DPP7ABCB1 | |
| SCHEMBL102512 | 0.97 | — | — | |
| SCHEMBL27143448 | 0.92 | — | — | |
| SCHEMBL28175746 | 0.88 | DPP7 (0.31) | DPP7ABCB1 | |
| SCHEMBL29187652 | 0.86 | TSHR (0.33) | — | |
| SCHEMBL1792180 | 0.86 | — | — | |
| SCHEMBL8959083 | 0.85 | ABCB1 (0.37) | DPP7ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0354040-A2 | Membranes prepared from blends of polybenzimidazole with polyarylates | HOECHST CELANESE CORPORATION (US) | 1990-02-07 | — | — | EP | claimed |
| WO-2024043341-A1 | CYCLOALKYNE DERIVATIVE | ペプチドリーム株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-1641759-B1 | MALONAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20130158076-A1 | Methylene Urea Derivatives | MERCK PATENT GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-8410143-B2 | Methylene urea derivatives | MERCK PATENT GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2426122-A1 | Methylene urea derivative as RAF kinasse inhibitors | Merck Patent GmbH (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-1653951-B1 | BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-8003657-B2 | Heterocyclic substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-1343769-B1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2003008392-A1 | 4-(BENZYLIDENE-AMINO)-3-(METHYLSULFANYL)-4H-(1, 2, 4) TRIAZIN-5-ONE DERIVATIVES HAVING A PDE-IV INHIBITING AND TNF-ANTAGONISTIC EFFECT FOR THE TREATMENT OF CARDIAC DISEASES AND ALLERGIES | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
| US-6417188-B1 | ENZYME INHIBITORS OF PHOSPHODIESTERASE | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-07-09 | — | — | US | disclosed |
| WO-2002051814-A1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1194411-A1 | BENZOYLPYRIDAZINES | MERCK PATENT GmbH (DE) | 2002-04-10 | — | — | EP | disclosed |
| EP-1173438-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2002-01-23 | — | — | EP | disclosed |
| EP-1087946-A1 | ARYL ALKANOYLPYRIDAZINES | MERCK PATENT GmbH (DE) | 2001-04-04 | — | — | EP | disclosed |
| WO-2001004099-A1 | BENZOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000063208-A1 | SUBSTITUTED IMIDAZOLES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-10-26 | — | — | WO | disclosed |
| WO-1999065880-A1 | ARYL ALKANOYLPYRIDAZINES | MERCK PATENT GMBH (DE) | 1999-12-23 | — | — | WO | disclosed |
| US-4791149-A | MIXING AND DISPENSING BY A PROPELLANT HYDROSILATION-CURABLE POLYSILOXANES AND A CATALYST FROM A MULTICOMPARTMENT PACKAGE | DOW CORNING FRANCE S.A. (FR) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158076-A1 | Methylene Urea Derivatives | BRAF, RAF1, CMPK1 | DPP7 3734/4885ABCB1 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.